Condensate Screening for Selective Macromolecule Association
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of understanding regarding the mechanisms governing the partitioning of a single macromolecule into or out of a condensate, and existing drug screening methods focus on disrupting entire condensates rather than selectively altering their composition or tissue specificity.
Innovation Solution
Methods are developed to identify compounds that selectively alter the association of macromolecules with condensates by determining and comparing association levels, enabling macromolecule, condensate, and tissue specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drug screening methods are used to disrupt entire condensates, then condensate disruption is achieved, but selectivity for specific macromolecules is lost
Solution Approach 1:
The patent segments the condensate system into individual macromolecule components, enabling selective targeting. Instead of treating the condensate as a homogeneous unit, the invention allows separate screening for compounds that specifically bind to or modulate individual macromolecules (e.g., FUS, TDP-43) within the condensate, thereby achieving both disruption efficacy and macromolecule selectivity
Solution Approach 2:
The invention applies local quality by creating distinct screening conditions for different macromolecules. Each macromolecule can be evaluated under its specific binding conditions, concentrations, and assay parameters, allowing compounds to exhibit selectivity for particular macromolecules based on their local chemical and physical environment within the condensate
2Adaptability or versatility
If compounds are screened to alter condensate composition, then macromolecule specificity is improved, but measurement precision requirements increase
Solution Approach 1:
The patent introduces intermediary detection methods such as fluorescently labeled macromolecules or proximity-dependent signaling molecules that mediate the measurement of association levels. These intermediaries amplify the signal from macromolecule-compound interactions, enabling precise detection of subtle changes in association levels without requiring direct measurement of the macromolecules themselves
Solution Approach 2:
The invention utilizes parameter changes in the detection system to enhance measurement precision. By varying parameters such as fluorescence intensity, binding affinity, or assay conditions, the method can detect small changes in macromolecule association levels with high precision, allowing specific compound effects to be distinguished from background noise
3Adaptability or versatility
If selective compound identification is implemented, then therapeutic specificity is improved, but screening complexity increases
Solution Approach 1:
The patent segments the screening process into modular stages: (1) condensate formation, (2) compound addition, (3) association level measurement, and (4) specificity calculation. This segmentation allows each stage to be optimized independently and facilitates high-throughput implementation, reducing overall screening complexity while maintaining therapeutic specificity
Solution Approach 2:
The invention simplifies screening complexity by using parameter changes in the data analysis phase. By calculating specificity based on quantitative changes in association levels (e.g., percentage change in macromolecule-condensate association), the method transforms complex biological interactions into simple, comparable numerical parameters that can be efficiently screened across large compound libraries
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable the identification of compounds that can selectively modulate condensate composition and tissue specificity, providing therapeutic strategies to treat diseases like neurodegenerative disorders while minimizing off-target effects.
Implementation Method 1
Numerous of these membrane-less molecular assemblies have been shown to be formed through a process termed liquid-liquid phase separation or condensation, in a manner analogous to the partitioning of oil droplets in water. During this process, e.g., a solution comprising biological macromolecules separates into different phases, namely, a condensate dense phase that is enriched in at least some of the biological macromolecules and a surrounding light phase.
Data Source
AI summary
Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.